C57BL/6JCya-Flt3em1/Cya
Common Name:
Flt3-KO
Product ID:
S-KO-02085
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Flt3-KO
Strain ID
KOCMP-14255-Flt3-B6J-VB
Gene Name
Product ID
S-KO-02085
Gene Alias
B230315G04; CD135; Flk-2; Flk2; Flt-3; Ly72; wmfl
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
5
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Flt3em1/Cya mice (Catalog S-KO-02085) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000049324
NCBI RefSeq
NM_010229
Target Region
Exon 3
Size of Effective Region
~1.0 kb
Detailed Document
Overview of Gene Research
Flt3, also known as FMS-like tyrosine kinase 3, is a receptor tyrosine kinase almost exclusively expressed in the hematopoietic compartment. Its ligand, FLT3 ligand (FL), induces dimerization and activation of its intrinsic tyrosine kinase activity. Activation of Flt3 leads to autophosphorylation and initiation of signal transduction cascades like STAT5, MAPK and AKT, mediating cell survival, proliferation, and differentiation of hematopoietic progenitor cells [4,5].
Mutations in the Flt3 gene are the most frequent genetic alteration in acute myeloid leukemia (AML), occurring in approximately 30% of all AML cases. The two major types are internal tandem duplication (ITD) in the juxtamembrane domain and point mutations or deletions in the tyrosine kinase domain (TKD). Flt3-ITD is the most common, present in about 25% of AML cases, associated with high leukemic burden, increased relapse, and poor prognosis. Flt3-TKD has a lower incidence (about 7-10% of cases), and its prognostic value is uncertain. Clonal evolution of Flt3 mutational status occurs during the disease. First-generation Flt3 inhibitors are broad-spectrum, while next-generation ones are more specific, but resistance to these inhibitors remains a challenge [1,2,3,4,7,8].
In conclusion, Flt3 is crucial for normal hematopoietic cell function through its signaling pathways. In AML, Flt3 mutations, especially Flt3-ITD, play a significant role in disease progression and prognosis. Understanding Flt3 through genetic models could potentially lead to better targeted therapies for AML patients. The development and use of Flt3 inhibitors, despite the resistance challenges, have already changed the treatment landscape for Flt3-mutated AML [1,2,3,4,6,7,8].
References:
1. Daver, Naval, Schlenk, Richard F, Russell, Nigel H, Levis, Mark J. 2019. Targeting FLT3 mutations in AML: review of current knowledge and evidence. In Leukemia, 33, 299-312. doi:10.1038/s41375-018-0357-9. https://pubmed.ncbi.nlm.nih.gov/30651634/
2. Kennedy, Vanessa E, Smith, Catherine C. 2020. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. In Frontiers in oncology, 10, 612880. doi:10.3389/fonc.2020.612880. https://pubmed.ncbi.nlm.nih.gov/33425766/
3. Negotei, Cristina, Colita, Andrei, Mitu, Iuliana, Stanca, Oana, Berbec, Nicoleta Mariana. 2023. A Review of FLT3 Kinase Inhibitors in AML. In Journal of clinical medicine, 12, . doi:10.3390/jcm12206429. https://pubmed.ncbi.nlm.nih.gov/37892567/
4. Kiyoi, Hitoshi, Kawashima, Naomi, Ishikawa, Yuichi. 2019. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. In Cancer science, 111, 312-322. doi:10.1111/cas.14274. https://pubmed.ncbi.nlm.nih.gov/31821677/
5. Kazi, Julhash U, Rönnstrand, Lars. . FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. In Physiological reviews, 99, 1433-1466. doi:10.1152/physrev.00029.2018. https://pubmed.ncbi.nlm.nih.gov/31066629/
6. Bystrom, Rebecca, Levis, Mark J. 2023. An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. In Current oncology reports, 25, 369-378. doi:10.1007/s11912-023-01389-2. https://pubmed.ncbi.nlm.nih.gov/36808557/
7. Arai, Yasuyuki, Chi, SungGi, Minami, Yosuke, Yanada, Masamitsu. 2022. FLT3-targeted treatment for acute myeloid leukemia. In International journal of hematology, 116, 351-363. doi:10.1007/s12185-022-03374-0. https://pubmed.ncbi.nlm.nih.gov/35532877/
8. Fedorov, Kateryna, Maiti, Abhishek, Konopleva, Marina. 2023. Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. In Cancers, 15, . doi:10.3390/cancers15082312. https://pubmed.ncbi.nlm.nih.gov/37190240/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen